Angelini Labopharm Announces the U.S. Launch of OLEPTRO™ for the Treatment of Major Depressive Disorder in Adults

Tuesday, August 10, 2010 Mental Health News
Email Print This Page Comment bookmark
Font : A-A+

OLEPTRO™ Now Available as a New Treatment Option for MDD

For Media Inquiries (Angelini Labopharm)

For Labopharm Investor Relations Inquiries

Michael Parks

Lawrence Chamberlain

Vox Medica, Inc.

Investor Relations

Tel: (267) 885-3066

Tel:  (416) 815-0700

mparks@voxmedica.com

lchamberlain@equicomgroup.com

For Media Inquiries (Angelini)

Fabio Pieroni

Angelini Corporate Communications Director

Tel: +39 06 78053366

f.pieroni@angelini.it

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store